EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische Studie

A Multi-Center, Randomized, Blinded Clinical Study Evaluating the Efficacy and Safety of a Novel Topical Product for Facial Dyschromia

Jordan Wang, Sabrina Fabi, Deanne Robinson, Shirin Bajaj, Roy Geronemus, Michaela Bell, Alan Widgerow

Journal of Drugs in Dermatology · 2023

DOI: 10.36849/jdd.7340 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Drugs in Dermatology, 2023. Verfasst von Jordan Wang und 6 weiteren Autor:innen. Hauptthemen laut MEDLINE: Dermatologic Agents, Hyperpigmentation, Melanosis.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatologic AgentsHyperpigmentationMelanosisHumansHydroquinonesTreatment OutcomeAdministration, Cutaneous

Substanzen

hydroquinoneHydroquinonesDermatologic Agents

Zitieren

APA

Wang, J., Fabi, S., Robinson, D., Bajaj, S., Geronemus, R., Bell, M., & Widgerow, A. (2023). A Multi-Center, Randomized, Blinded Clinical Study Evaluating the Efficacy and Safety of a Novel Topical Product for Facial Dyschromia. Journal of Drugs in Dermatology. https://doi.org/10.36849/jdd.7340

Vancouver

Wang J, Fabi S, Robinson D, Bajaj S, Geronemus R, Bell M, et al. A Multi-Center, Randomized, Blinded Clinical Study Evaluating the Efficacy and Safety of a Novel Topical Product for Facial Dyschromia. Journal of Drugs in Dermatology. 2023. doi:10.36849/jdd.7340

BibTeX
@article{Wang2023,
  author = {Wang, Jordan and Fabi, Sabrina and Robinson, Deanne and Bajaj, Shirin and Geronemus, Roy and Bell, Michaela and Widgerow, Alan},
  title = {A Multi-Center, Randomized, Blinded Clinical Study Evaluating the Efficacy and Safety of a Novel Topical Product for Facial Dyschromia},
  journal = {Journal of Drugs in Dermatology},
  year = {2023},
  doi = {10.36849/jdd.7340}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche